AACR 2025 | ctDNA-guided PD-1 blockade in resected early-stage MMRd tumors
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a prospective study evaluating pembrolizumab in patients with resected mismatch repair deficient solid tumors and circulating tumor DNA (ctDNA)-detected minimal residual disease (MRD). Patients with positive ctDNA received PD-1 blockade, while ctDNA-negative patients were observed. High rates of ctDNA clearance and promising recurrence-free and overall survival outcomes were observed among treated patients. Findings suggest ctDNA-guided immunotherapy may offer clinical benefit across multiple tumor types following surgery. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
